Tyme Technologies — Investor Presentation (September 2017)
27 slides from Tyme Technologies's investor presentation, Sep 11, 2017
Slide 1: The Future of Cancer Treatments
Exhibit 99.1 TYMEO) the FUTURE of CANCER TREATMENTS SEPTEMBER 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk fac
Slide 3: Tyme Overview
Tyme Overview Selectively target cancer through its altered metabolism and dependence on tyrosine Use a tumor’s natural function to cause apoptosis from oxidative stress Complete and partial responses with monotherapy in 13 different types of progressive, metastatic cancer Median survival in metasta
Slide 4: SM-88 and Tyme at a Glance
SM-88 and Tyme at a Glance Oral tyrosine-based therapy for cancer Over 5 years of clinical data in more than 100 metastatic subjects No drug-related SAEs to date First human study, completed (n=30) Monotherapy in end stage progressive metastatic cancers Median OS of 27.5 months 90% clinical benefit
Slide 5: ECOG Performance Status and First Human Study Summary
ECOG Performance Status* Following 1 Cycle of SM-88 (n = 30) Number of Subjects Score Start End 0 1 14 1 15 14 2 10 2 3 3 0 4 1 0 5 0 0 Average 1.6 0.6 * Eastern Cooperative Oncology Group Performance Score score: 0 (asymptomatic), 1-3 (symptomatic) , 4 (bedbound), 5 (death). SM-88: First Human Stud
Slide 6: FHS Median Overall Survival 27.5 months
FHS Median Overall Survival 27.5 months All Subjects (n = 30), Monotherapy with SM-88 90% of subjects experienced clinical benefit (CR, PR or SD)1 All subjects entered with progressing metastatic disease OS substantially exceeded expectations Subjects entered with 3-6 months expected survival Treatm
Slide 7: Stable Disease Designation with SM-88
Subject 040 KG failed two lines of systemic therapy in addition to surgery before entering the trial. Subject is still alive more than five years after initiating SM-88 therapy and has had no other cancer therapies Standardized uptake value (SUV) is a measurement of tumor metabolism using positron e
Slide 8: SM-88: First Human Study Safety Profile
SM-88: First Human Study Safety Profile Median SM-88 exposure: 16.3 weeks, (range: 6-61 weeks) Adverse Events Reported in the First Human Study (n=30)1 Adverse EventGrade 1Grade 2 Grade 3/4 Total 29 (97%)1 (3%) - 30 (100%) 13 (43%)4 (13%) - 17 (57%) 3 (10%)1 (3%) - 4 (13%) 1 (3%)- - 1 (3%) 1 (3%)- -
Slide 9: Common Ties Between Cancers
Common Ties Between Cancers Discovered in the 1920s Shows that cancer produces energy differently than normal cells Relies on a more primitive metabolic process, called aerobic glycolysis Highly inefficient use of glucose Produces a high level of free radicals (“ROS”) Drives reliance on amino acids
Slide 10: Breaking the Metabolic Circuit of Cancer
Breaking the Metabolic Circuit of Cancer 3) Protective Mucin Layer Compromised 4) Cell Death From Oxidative Stress Immune Response Free Radicals (ROS) 2) Protein Synthesis Fails 1) Induce Uptake of Tyme’s Dysfunctional Tyrosine
Slide 11: SM-88 Composition and Function
Dysfunctional Tyrosine Derivative SM-88 Composition and Function Non-nutritive tyrosine analogs disrupt cancer’s creation of proteins, including mucin Rapamycin* mTOR inhibitor decreases insulin function and increases tyrosine uptake * Microdose: <25% of recommended therapeutic dosing levels CELL DE
Slide 12: Clinical Development Pipeline
Clinical Development Pipeline Program Formulation Cancer Indication Pre-IND Phase I Phase II Phase III SM-88 Oral Prostate, recurrent non-metastatic Pancreatic, metastatic 3rd Indication, Metastatic Injectable Digestively compromised patients Nasal Glioma Transdermal Breast Tyrosine-bound Melanin Or
Slide 13: Current and Planned Trials
Current and Planned Trials TYMEO
Slide 14: Rationale for Prostate Cancer Application
Rationale for Prostate Cancer Application Third most prevalent cancer 160,000 new cases in US in 2017 27,000 deaths in US in 2017 Multibillion dollar drug market Radiotherapy Prostatectomy Market Stats Lower side effect profile Maintain testosterone levels Chronic administration as maintenance thera
Slide 15: Phase Ib/II Biomarker-Recurrent Prostate Cancer Trial Design
No progression events Decrease CTC Maintain testosterone Maintain quality of life No additional toxic therapy Improve PSA doubling Phase Ib/II Biomarker-Recurrent, Non-Metastatic Prostate Cancer Trial Design Phase Ib: dose-escalation phase (n=4), completed Jan 2017 Both 230mg and 460mg tyrosine dose
Slide 16: Summary of Ongoing Phase Ib/II Prostate Trial
Summary of Ongoing Phase Ib/II Trial in Biomarker Recurrent Prostate Cancer Efficacy Endpoint Evaluable response (n=9) Radiographic progression free survival (rPFS) 100.0% Improvement in circulating tumor cells All subjects Need for subsequent toxic therapy None Average improvement in PSA doubling 1
Slide 17: Rapid Circulating Tumor Cell Response
Rapid Circulating Tumor Cell Response CTCs are tumor cells that are carried in the blood and may be an early indicator of metastatic disease All subjects had an improvement in CTC levels and 67% (6/9) had an 80% or greater decline Indexed Circulating Tumor Cell Levels Per Patient Month
Slide 18: Preliminary Safety Results
No grade 2 or higher drug-related adverse events >55 months of cumulative daily oral dosing experience Maintained quality of life in patient reported intimacy outcomes In comparison, QOL in this area would be expected to decline if patient was chemically castrated with ADT therapy Phase Ib/II Biomar
Slide 19: Pancreatic Cancer Statistics
Pancreatic Cancer Statistics 1.American Cancer Society Current prognosis for pancreatic cancer is 80% mortality in first year Five-year survival rate for metastatic stage of 1% Standard-of-care results from recent clinical trials: First-line Abraxane + gemcitibine: median OS of 8.5m and CR+PR of 23%
Slide 20: Existing SM-88 Data for Pancreatic Cancer
Existing SM-88 Data for Pancreatic Cancer 1.Note: Patients in the compassionate use program may differ from treatment protocol in the First Human Study Summary of Metastatic Pancreatic Cancer Patients Treated with SM-88 First Human Study Patient Overall Survival (months) Duration on SM-88 (months) R
Slide 21: Planned Phase II Trial: Metastatic Pancreatic Cancer
Planned Phase II Trial: Metastatic Pancreatic Cancer Structure: Open-Label Enrollment: ~100 patients (2 stages) End Points: PFS, OS, Response Rate Stage 2 Stage 1 Indication Refractory Metastatic Pancreatic Cancer Patients (2L/3L) Interim Analysis SM-88 Monotherapy Sites: ~35 across North America CR
Slide 22: Historical Results Offer Multiple Paths Forward
Historical Results Offer Multiple Paths Forward CR/PR Shown in 13 Different Tumor Types Source: American Cancer Society. Objective Response Rate (“ORR”) based on imaging analysis using RECIST 1.1 criteria. Includes both First Human Study and Compassionate Use Patients. Primary Disease 2016 U.S. Data
Slide 23: Corporate Profile
Corporate Profile TYMEO
Slide 24: Corporate History
Corporate History Virtual company funded by founders Mission to help patients that have failed or refused all other options Treated >80 advanced metastatic cancer patients with a New York hospital Established proof-of-concept First outside funding Launched Phase Ib/II prostate trial under Tyme IND I
Slide 25: Management & Board
Management & Board Founders Other Executives Board & MAB Chairman, CEO & CSO Steve Hoffman Authored >30 issued patents Director & COO Michael Demurjian >25 years repeated entrepreneur President & CFO Ben Taylor Chief Medical Officer Dr. Giuseppe Del Priore Chief Scientific Affairs Officer Jon Eckard
Slide 26: Recent Achievements and Upcoming Objectives
Recent Achievements and Upcoming Objectives Positive interim Phase Ib/II prostate cancer data presented at ESMO 2017 Five data presentations/publications at ASCO 2017 Preclinical toxicology data released at ESMO 2016 Four core platform patents issued Raised funding for Phase II metastatic pancreatic
Slide 27: WALL STREET 12TH FLOOR NEW YORK, NY 10005 [email protected] TYMEINC.COM
44 WALL STREET 12TH FLOOR NEW YORK, NY 10005 NASDAQ: TYME [email protected] TYMEINC.COM
Tyme Technologies — Investor Presentation (September 2017) on 6ix